PQT/MED publishes first invitation to manufacturers of medicinal products for treatment of disorders caused by use of tobacco, to submit an Expression of Interest (EOI)

A first invitation to manufacturers of medicinal products for treatment of disorders caused by use of tobacco, to submit an Expression of Interest (EOI) for product evaluation has been published by the WHO Prequalification Unit (PQT).

The below product was added to the EOI:

Single ingredient medicine to treat disorders due to use of tobacco

• Nicotine replacement therapy (Chewing gum: 2 mg; 4 mg as polacrilex. Transdermal patch: 5 mg to 30 mg/16 hours; 7 mg to 21 mg/24 hours)